-
An article combing: Exploration of immunotherapy resistance mechanism and antimicrotherapy strategy of advanced NSCLC without driver gene mutation
Time of Update: 2023-02-02
In a follow-up phase II study, the investigators are exploring the efficacy of JTX-4014, a novel PD-1 monoclonal antibody, ± vopratelimab, in patients with high ICOS expression, EGFR wild-type, platinum-containing therapy progression, and no immunotherapy NSCLC.
-
Heavy! Liu Dingbin/Xu Chen of Nankai University discovered novel biomarkers that can be used as non-invasive diagnosis and prognosis of colorectal cancer
Time of Update: 2023-02-02
Referrals, live broadcasts/events01/12 14:00-16:00 OnlineOlink Multiomics Cohort ForumScan the code to participate for free03/02-03 09:00-18:00 ShanghaiThe 2nd Yangtze River Delta Single-cell Omics Technology Application ForumScan the code to participate for freeThis article is the original of Translational Medicine Network, please indicate the source for reprintingWritten by SophiaColorectal cancer (CRC) is one of the most common malignancies and is usually detected late in the clinic.
-
Low-grade gliomas in children in the era of molecular diagnostics
Time of Update: 2023-02-02
Scott Ryall of the University of Toronto, Canada, reviewed the molecular characteristics, targeted therapy pathways, corresponding detection platforms, and diagnostic treatment procedures of pLGG, which provided a decision-making basis for the precise diagnosis and treatment of pLGG.
-
What are the types of multiple myeloma? What are the prognostic effects? See what the latest guide has to say!
Time of Update: 2023-02-02
Author: Blue Whale XiaohuThis article is authorized by the author to be published by Yimaitong, please do not reprint it without authorization. Multiple myeloma (MM) accounts for 1% of all cancers and
-
Professor Wang Rongqi: Management of immune-related adverse reactions
Time of Update: 2023-02-02
Table 1 Current clinical ICIsThe mechanism of irAEs is as follows:Disrupt the original immune tolerance balance, so that autoimmune strengthening triggers irAE;Tumor cells release host antigens during treatment, and antigen cross-presentation occurs, triggering an autoimmune response;Immune cells release inflammatory mediators leading to tissue immune damage;off-target effects of ICls;The pro-inflammatory effect of microorganisms exacerbates the pro-inflammatory effect in the treatment of ICIs, causing irAE.
-
Get to the point! You need to know these changes in the 2022 CSCO guidelines for the diagnosis and treatment of small cell lung cancer
Time of Update: 2023-02-02
smallknotIn general, the update of the 2022 edition of the CSCO guidelines for the diagnosis and treatment of small cell lung cancer mainly focuses on the treatment of extensive-stage SCLC, especially the recommended upgrade of chemotherapy + immunotherapy regimen for first-line therapy.
-
Science publishes two articles in a row: CAR-T cells are upgraded again, or will eradicate deadly solid tumors!
Time of Update: 2023-02-02
In another study published Dec. 16 in Science, a team of researchers from the University of California, San Francisco used the recently developed synthetic Notch receptor to design enhanced CAR-T cells with a second receptor that recognizes tumor antigens and subsequently causes T cells to release the cytokine interleukin-2 (IL-2).
-
Demon Dictionary: inflammation, hyperplasia, cancer, invasion, metastasis...
Time of Update: 2023-02-02
Endometrial hyperplasiaNeoplasia: A massive lumpy protrusion, also called neoplasm, is a manifestation of the proliferation of local tissue cells in the body 。 Polyps, commonly known as polyps, are protruding vegetations on the mucosal surface, including hyperplastic, inflammatory, hamartoma, adenoma, and other tumors.
-
New directions of immune combination: exploration of PD-L1 inhibitors combined with PARP inhibitors in solid tumors
Time of Update: 2023-02-02
prefaceImmune checkpoint inhibitors (ICIs) are effective in the treatment of a variety of solid tumors as monotherapy or in combination with other drugs. Preclinical data and early clinical trials hav
-
Medical interview with Professor Li Sheng: improving the preservation rate and preoperative pathological remission rate of rectal cancer, and also recommended by international guidelines, the whole process of neoadjuvant therapy has become a "new trend" in colorectal cancer treatment
Time of Update: 2023-02-02
2 PRODIGE23 STUDY, COMPARING THE DISEASE-FREE SURVIVAL RATE (A) AND OVERALL SURVIVAL RATE (B) OF TNT TREATMENT WITH TRADITIONAL "SANDWICH MODE" TREATMENT 03Recommend the whole process of neoadjuvant therapy to update doctors' new treatment ideasAt present, foreign countries have promoted the TNT model, from the short-term and long-term benefits of various studies, rectal cancer patients survival benefits and organ function retention, TNT can increase preservation rate, pCR, DFS and RFS has also improved.
-
CRISPR transforms cancer cells to become anti-cancer weapons, can in situ tumor vaccines attack solid tumors?
Time of Update: 2023-02-02
In short, in order to break through the microenvironment challenges of solid tumors, scientists are innovating to try a variety of different therapies and combinations, and I believe that humans will one day overcome them!The concept of tumor in situ vaccines has been proposed for a long time, and products have entered clinical trials, but there are currently few clinical data published.
-
【STTT】This anti-allergy drug is expected to fight cancer! Li Bin's team from Guangzhou Medical University discovered a new therapeutic target for liver cancer
Time of Update: 2023-02-02
1038/s41392-022-01248-9The low survival rate of patients with hepatocellular carcinoma needs to be improved 01 01 As the most common type of liver cancer, hepatocellular carcinoma (HCC) has a poor prognosis and is the fourth leading cause of cancer-related death worldwide.
-
Scientists used the F-19 MRI dual-modal probe to achieve accurate in vivo imaging of nitroreductase in lung cancer
Time of Update: 2023-02-01
Recently, the research team of Zhou Xin, a researcher at the Institute of Precision Measurement Science and Technology Innovation of the Chinese Academy of Sciences, designed and constructed a dual-modal molecular probe Nitrofluoride Cy7, which realized the 19F magnetic resonance and near-infrared fluorescence accurate imaging of nitroreductase in living lung cancer.
-
【CA】The United States released the latest annual cancer report, and deaths from new crown infections accounted for two-thirds of the increase!
Time of Update: 2023-02-01
Overall mortality trends are primarily driven by lung cancer, and in recent years, lung cancer has declined similarly in men and women due to treatment advances that have prolonged survival, as well as early detection.
-
Professor Qian Wenbin's team published the results of the salvage chemotherapy regimen of R/R DLLBCL
Time of Update: 2023-02-01
Recently, based on the development of related research fields at home and abroad, the team of the Department of Hematology of the Second Hospital of Zhejiang University published an original research
-
Professor Wang Shusen: Looking at the comprehensive benefits of CDK4/6 inhibitors, exploring the way to break the drug resistance| review of the annual progress of breast cancer treatment in 2022
Time of Update: 2023-02-01
On January 7, 2023, the "2022 Annual Progress Review of Breast Cancer Treatment", a grand event in the field of breast cancer, opened in Beijing. The conference reviewed the important academic progres
-
Tislelizumab shines in the MIBC neoadjuvant treatment HOPE-03 study
Time of Update: 2023-02-01
2Study designThe HOPE-3 study is a multicenter, single-arm, open-label phase Ib/II clinical study led by Professor Zhang Peng and Professor Shen Yali, a subspecialty MDT team of urological oncology and bladder in West China Hospital, aiming to explore the efficacy and safety of vedicitumab combined with tislelizumab as neoadjuvant therapy in patients with HER2-positive locally progressive MIBC, hoping to improve the tumor response rate of patients and obtain long-term survival benefits through the combination therapy of the two.
-
Professor Shen Bo: "Lung" often fights "epidemic" - diagnosis and treatment and protection of lung cancer patients under the new crown epidemic
Time of Update: 2023-02-01
Since December 2022, many places have experienced the pandemic phase of new crown infection, and the number of infection cases has increased in the short term. Due to immunocompromised and other reaso
-
More than 190,000 people study: such women have a 137% increased risk of breast cancer!
Time of Update: 2023-02-01
Based on breast cancer screening data from nearly 190,000 women in Denmark, the study found that women with higher breast density (dense type) had a significantly increased risk of breast cancer by 137% compared to women with lower breast density (fatty breasts).
-
Is KEYNOTE-394 the "icing on the cake" or "a thriving"?
Time of Update: 2023-02-01
In 2022, with the positive results of the international multi-center, phase III clinical study KEYNOTE-394 enrolled in 85% of Chinese patients, the indication of PD-1 immune checkpoint inhibitor pembrolizumab (commonly known as "K drug") for the treatment of advanced primary hepatocellular carcinoma (HCC) treated by previous sorafenib or oxaliplatin chemotherapy was approved in China.
